SCHEMBL21189493

SCHEMBL21189493

O=C(Nc1ccc(F)c(Cl)c1)c1c(F)ccc2c1OCCC2

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.55
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
NPSR1 Q6W5P4 2/20 0.53
MAPT P10636 3/20 0.46
LMNA P02545 1/20 0.46
TSHR P16473 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
SLC2A1 P11166 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HTT P42858 2/20 0.45
ALDH1A1 P00352 1/20 0.45
FADS1 O60427 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21189280 0.84 FADS1 (0.54) SMN1; SMN2NPC1RAB9ANPSR1MAPT
SCHEMBL19973426 0.81 NPSR1 (0.52) SMN1; SMN2NPC1RAB9ANPSR1MAPT
Hydrochloric Acid SCHEMBL19973611 0.76 NPC1 (0.46) SMN1; SMN2NPC1RAB9ANPSR1MAPT
SCHEMBL19973566 0.74 KMT2A (0.46) SMN1; SMN2NPC1RAB9ANPSR1MAPT
SCHEMBL19973567 0.74 KMT2A (0.46) SMN1; SMN2NPC1RAB9ANPSR1MAPT
SCHEMBL8948607 0.74 CAT (0.40) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL15786683 0.74 FADS1 (0.55) SMN1; SMN2NPC1RAB9ANPSR1MAPT
SCHEMBL21189257 0.72 MEN1 (0.44) SMN1; SMN2NPC1RAB9ANPSR1MAPT
SCHEMBL21189535 0.72 MEN1 (0.44) SMN1; SMN2NPC1RAB9ANPSR1MAPT
SCHEMBL19973470 0.72 MEN1 (0.47) SMN1; SMN2NPC1RAB9ANPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS SMN1; SMN2 3837/4885NPC1 983/4885RAB9A 1393/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS SMN1; SMN2 3837/4885NPC1 983/4885RAB9A 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.